诊断性宫腔镜检查对II型子宫内膜癌是否安全?回顾性队列分析
HSC组腹膜细胞学阳性率为4.6%(2/43),D&C组为10.7%(9/84),差异无统计学意义(p=.22)。两组无病生存和疾病特异性生存曲线无显著差异。结论认为诊断性HSC不增加手术分期时腹膜细胞学阳性率,可能和D&C一样安全。
要点
- II型子宫内膜癌患者诊断性HSC后腹膜细胞学阳性率4.6%,与D&C的10.7%无显著差异。
- HSC组与D&C组的无病生存和疾病特异性生存曲线无统计学差异。
- 多因素分析显示晚期 stage 和血管浸润与复发/死亡风险增加相关。
核心结论
- 诊断性HSC不增加II型子宫内膜癌患者手术分期时腹膜细胞学阳性率,可能和D&C一样安全。
主要发现
- HSC组腹膜细胞学阳性2/43(4.6%),D&C组9/84(10.7%),p=.22。
- D&C组晚期癌症 stage 和 greater vascular invasion 更常见(p=.008和p=.04)。
- 两组无病生存和疾病特异性生存曲线无统计学差异。
- 多因素分析显示,晚期 stage(III/IV)(HR=4.67; 95%CI 2.34-9.34; p<.001)和高龄(HR=1.08; 95%CI 1.04-1.13; p<.001)与复发相关。
- 对于疾病特异性生存,高龄(HR=1.08; 95%CI 1.05-1.12; p<.001)、stage III/IV(HR=3.95; 95%CI 2.18-7.15; p<.001)和血管浸润(HR=2.47; 95%CI 1.34-4.54; p=.004)增加死亡风险。
临床怎么用
- 对于怀疑II型子宫内膜癌的患者,诊断性HSC可用于评估宫腔,不增加腹膜细胞学阳性风险。
- 临床决策时需综合考虑 stage、年龄和血管浸润等预后因素。
局限性
- 回顾性设计可能存在选择偏倚,D&C组晚期 stage 和血管浸润更常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Although hysteroscopy (HSC) can be used for assessing the uterine cavity in women with suspected endometrial cancer (EC), it remains controversial as a procedure because it can potentially enhance the metastatic spread of cancer cells. Moreover, it is important to assess this hypothesis for type II EC, a more aggressive phenotype that usually presents with endometrial atrophy and has worse prognosis. Thus, we aimed to assess the prevalence of positive peritoneal cytology result in women with type II EC who underwent HSC as a diagnostic tool and to determine the factors associated with patient relapse/survival. DESIGN: Retrospective cohort analysis (2002-2017). SETTING: Tertiary, academic hospital. PATIENTS: One hundred twenty-seven women with type II EC. INTERVENTIONS: Diagnostic HSC (HSC) (n = 43) or dilation/curettage (D&C) (n = 84). MEASUREMENTS AND MAIN RESULTS: Primary end point was the frequency of positive peritoneal cytology result. Survival curves were projected using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis with hazard ratio (HR) and 95% confidence intervals (CIs) were calculated to assess the factors related with the disease-free survival (DFS) and the disease-specific survival (DSS). Advanced cancer stage and greater vascular invasion appeared more frequently in the D&C group (p = .008 and p = .04, respectively). Positive peritoneal cytology result was present in 2 of 43 (4.6%) women following HSC and in 9 of 84 (10.7%) following D&C (p = .22). DFS and DSS curves did not statistically differ between the groups. Multivariate analysis for DFS revealed that advanced cancer stage (III and IV) (HR = 4.67; 95% CI, 2.34-9.34; p <.001) and advanced age (HR = 1.08; 95% CI, 1.04-1.13]; p <.001) were the factors associated with relapse. For DSS, advanced age (HR = 1.08; 95% CI, 1.05-1.12; p <.001), cancer stage III/IV (HR = 3.95; 95% CI, 2.18-7.15; p <.001), and vascular invasion (HR = 2.47; 95% CI, 1.34-4.54; p = .004) increased the risk of mortality. CONCLUSION: Diagnostic HSC did not increase the rate of positive peritoneal cytology result at the time of surgical staging in this cohort of women with type II EC and is probably as safe as D&C.
引用
- Ribeiro CM, Brito LGO, Benetti-Pinto CL, et al. Is Diagnostic Hysteroscopy Safe for the Investigation of Type II Endometrial Cancer? A Retrospective Cohort Analysis. J Minim Invasive Gynecol. 2021. PMID: 33444791. doi:10.1016/j.jmig.2021.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。